Section
The Chan Zuckerberg Biohub's Virtual Biology Initiative expanded to a combined $1.8 billion in funding, data and compute from the DOE, NIH, DeepMind, Isomorphic Labs and Meta, betting that AI drug discovery's bottleneck has shifted from models to verifiable biological data.
The APLMS launched a pilot Singapore–China–India Healthy Longevity Model, prioritizing real-world evidence, functional outcomes, and scalable prevention over biomarkers alone across a 2.8 billion-person region. No trial results were reported.
The 2026 Nobel Prize in Physiology or Medicine goes to Karl Deisseroth, Peter Hegemann and Georg Nagel for light-controlled ion channels and optogenetics, per the source brief. No primary papers or trial data are included, and clinical benefit is not established.
Machine learning is transforming medical devices but faces challenges like shortcut learning and automation bias. Edge AI and evolving regulation aim to balance innovation with safety.
Philips recovered €186 million in U.S. tariff refunds during Q2 2025, while grappling with cost inflation, China headwinds, and currency effects. Strong demand in North America and Europe and emerging opportunities in India were highlighted.
Boston Scientific slashed its 2026 sales and EPS forecasts for the second straight quarter, citing competitive pressure in pulsed field ablation and declining standalone Watchman procedures.
Dexcom buys Nutrisense and updates Stelo app with AI; Insulet lowers Omnipod 5 target to 100 mg/dL; Beta Bionics shares real-world iLet HbA1c data.
The 2026 Fortune Global 500 includes 25 healthcare companies. Eli Lilly rose 112 spots to 224th, and McKesson entered the top 10 for the first time.
